Acquisition leverage MNG Laboratories was acquired by LabCorp in 2019, indicating strong validation and potential access to LabCorp’s broader distribution, client networks, and sales channels for neurogenetic testing.

NEurogenetic focus Specializes in neurogenetic and complex biochemical testing with panels for movement disorders, epilepsy, muscular dystrophies, and intellectual disabilities, suggesting cross-sell opportunities to diagnostic labs, academic medical centers, and specialty clinics seeking comprehensive genetic testing.

Global recognition Internationally recognized capabilities and proprietary tools (Genome MaNaGer™ database, Neurogenetic Answers™ reporting) position MNG as a premium partner for outsourced testing, enabling partnerships with hospitals, research institutions, and payer-driven networks seeking advanced analytics.

Growth signals Recent expansions, such as mtDNA sequencing and deletion analysis, and a distribution partnership with Pronto Diagnostics, indicate openness to new services and markets, presenting upsell opportunities for additional sequencing panels and regional deployment.

Moderate scale Smaller company footprint with 11-50 employees and revenue in the low millions suggests agility for targeted enterprise deals, managed services, and pilot programs with mid-market clinics, private equity-backed groups, or multi-site health systems seeking specialized neurogenetic testing.